Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Pinter-Brown Discusses Treatment Decisions for CTCL

May 14th 2013

Lauren Pinter-Brown, MD, Clinical Professor, Department of Medicine, Hematology-Oncology, University of California, Los Angeles, discusses the treatment of cutaneous T-cell lymphoma.

Conclusion: Final Thoughts on Managing Hodgkin Lymphoma

May 10th 2013

Novel Treatment Approaches in Hodgkin Lymphoma

May 10th 2013

Allogeneic Transplantation in Hodgkin Lymphoma

May 10th 2013

Utilization of Brentuximab Vedotin in Hodgkin Lymphoma

May 10th 2013

Autologous Transplantation in Hodgkin Lymphoma

May 10th 2013

Treating Relapsed and Refractory Hodgkin Lymphoma

May 10th 2013

The Role of PET Imaging in Hodgkin Lymphoma

May 10th 2013

Primary Management of Advanced Hodgkin Lymphoma

May 10th 2013

Management of Hodgkin Lymphoma in Elderly Patients

May 10th 2013

Reducing Therapy-Related Toxicity in Hodgkin Lymphoma

May 10th 2013

Optimizing Radiation Therapy in Hodgkin Lymphoma

May 10th 2013

Risk-Adapted Approaches in Hodgkin Lymphoma

May 10th 2013

What Really Matters?

May 9th 2013

Discussing prognosis and a treatment plan has been getting particularly complicated with acute myelogenous leukemia with the development and use of molecular markers that confer prognostic and therapeutic information.

Dr. Jennifer Brown Discusses Rituximab and Ibrutinib in CLL

May 9th 2013

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the use of rituximab and ibrutinib in chronic lymphocytic leukemia.

Dr. Mesa on Ruxolitinib in Chronic Myeloid Leukemia

May 8th 2013

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses the mechanism of action of ruxolitinib in chronic myeloid leukemia.

JAK2 Inhibitor Shows Promise in Myelofibrosis

May 8th 2013

The strategy of targeting aberrant signaling in the JAK pathway appears promising thus far for SAR302503, an oral agent in development for the treatment of myelofibrosis.

Dr. Advani Discusses Front-Line Brentuximab

May 6th 2013

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses the movement of brentuximab vedotin combined with CHOP to the front-line.

Dr. Melnick on the Epigenetic Basis of B-Cell Lymphomas

May 2nd 2013

Ari M. Melnick, MD, Professor of Medicine, Weill Cornell Medical College, discusses his presentation on the epigenetic basis of B-cell lymphomas at the 17th International Congress on Hematologic Malignancies.

Dr. Cheson on Targeting PD-1 in Hematologic Malignancies

May 1st 2013

Bruce D. Cheson, MD, from the Georgetown Lombardi Comprehensive Cancer Center, discusses the investigation of PD-1 targeted agents as treatments for patients with lymphoma.